Indian stocks: Visit www.stage2stocks.com →

VolitionRX Limited

Stage 4 · Declining · week 50

As of Oct 22, 2026, VolitionRX is in Stage 4, the downtrend phase, now in week 50 (since Oct 27, 2025). It closed at $0.17, 98.1% below its 52-week high and below its 200-day average, which is falling.

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. More about the company

$0.17
+4.94% today
$5.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VNRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 20w
S4 23w
S4 26w
S4 52w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 20w → S1 13w → S4 23w → S1 13w → S4 26w → S1 4w → S2 8w → S3 6w → S4 52w current
Total tracked: 166 weeks across 9 stage runs.

VNRX among Medical Devices129th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…129VNRXStage 4 · wk 503−32.0%
vs 52W High
-98.1%
$0.16 lo$9.00 hi
98.1% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 50
1w13w26w
Week 50, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-92.8%
200 DMA: $2.36 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.16x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-32.0%
3M
-83.0%
6M
-93.9%
YTD
-96.9%
1Y
-98.0%
Scan Membership
Breakout Watch
Latest: 2023-01-13
6 appearances in last 60 days. First seen: 2018-10-26.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 50 · Vol 0.16x
2026-10-21S4
Wk 50 · Vol 0.04x
2026-10-20S4
Wk 50 · Vol 0.06x
2026-10-19S4
Wk 50 · Vol 0.11x
2026-10-16S4
Wk 49 · Vol 0.05x
2026-10-15S4
Wk 49 · Vol 0.13x
2026-10-14S4
Wk 49 · Vol 0.09x
2026-10-13S4
Wk 49 · Vol 0.17x
2026-10-12S4
Wk 49 · Vol 0.07x
2026-10-09S4
Wk 48 · Vol 0.10x
2026-10-08S4
Wk 48 · Vol 0.08x
2026-10-07S4
Wk 48 · Vol 0.13x
Moving averages & range
50 DMA
$0.31
200 DMA
$2.36
52W High
$9.00
52W Low
$0.16
5D Low
$0.16
Resistance levels (recent highs)
20d High
$0.26
60d High
$0.80
120d High
$3.13
250d High
$9.00
Next resistance
+52.9%
to 20d High
Dividend Yield
0.00%
P/B -0.1

VolitionRX: quick answers

What stage is VolitionRX in?

As of Oct 22, 2026, VolitionRX (VNRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 27, 2025 and is in week 50. What the four stages mean

Is VolitionRX in an uptrend?

No. VolitionRX is in a Stage 4 downtrend. It trades 92.8% below its 200-day average, which is falling.

How far is VolitionRX from its 52-week high?

VolitionRX closed at $0.17 on Oct 22, 2026, 98.1% below its 52-week high of $9.00. Its 52-week low is $0.16.

How has VolitionRX performed over the past year?

As of Oct 22, 2026, VolitionRX is down 98.0% over the past year and down 96.9% so far in 2026.

Which sector and industry is VolitionRX in?

VolitionRX is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.